The COVID-19 vaccine developed by Pfizer and BioNTech is on the table Thursday at a US Food and Drug Administration advisory committee hearing.
The FDA’s Vaccines and Related Biological Products Advisory Committee will meet virtually to review the vaccine trial data and discuss emergency use authorization for the companies’ coronavirus vaccine candidate.
The panel provides advice to the agency, which will ultimately decide whether to authorize emergency use — and make it the first COVID-19 vaccine approved in the US.
Pfizer and BioNTech said their vaccine is 95 percent effective, with no serious side effects.
The meeting, which begins at 9 a.m., will include a public comment portion and will livestream on the FDA’s YouTube channel and Twitter account.